BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

973 related articles for article (PubMed ID: 19281327)

  • 1. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.
    Maertens J; Theunissen K; Verhoef G; Verschakelen J; Lagrou K; Verbeken E; Wilmer A; Verhaegen J; Boogaerts M; Van Eldere J
    Clin Infect Dis; 2005 Nov; 41(9):1242-50. PubMed ID: 16206097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empirical antifungal therapy in treating febrile neutropenic patients.
    Wingard JR
    Clin Infect Dis; 2004 Jul; 39 Suppl 1():S38-43. PubMed ID: 15250019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study.
    Tan BH; Low JG; Chlebicka NL; Kurup A; Cheah FK; Lin RT; Goh YT; Wong GC
    Int J Infect Dis; 2011 May; 15(5):e350-6. PubMed ID: 21397541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
    Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
    Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.
    Hebart H; Klingspor L; Klingebiel T; Loeffler J; Tollemar J; Ljungman P; Wandt H; Schaefer-Eckart K; Dornbusch HJ; Meisner C; Engel C; Stenger N; Mayer T; Ringden O; Einsele H
    Bone Marrow Transplant; 2009 Apr; 43(7):553-61. PubMed ID: 19079316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical antifungal therapy in febrile neutropenic patients: current status.
    Kibbler CC
    Curr Top Med Mycol; 1997 Dec; 8(1-2):5-14. PubMed ID: 9504062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antimicrobial prophylaxis and therapy in neutropenia].
    Link H
    Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
    Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
    Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
    Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of invasive fungal diseases in neutropenic patients.
    Almyroudis NG; Segal BH
    Curr Opin Infect Dis; 2009 Aug; 22(4):385-93. PubMed ID: 19506476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients.
    Rieger CT; Ostermann H
    Mycoses; 2008; 51 Suppl 1():31-4. PubMed ID: 18471159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis.
    Karthaus M; Hentrich M
    Mycoses; 2011 Jan; 54 Suppl 1():1-6. PubMed ID: 21126265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques.
    Sobel JD
    Pharmacotherapy; 2006 Jun; 26(6 Pt 2):47S-54S. PubMed ID: 16716122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.